U.S. Home Infusion Therapy Market Value to Reach USD 38.02 billion by 2032; Economic & Clinical Advantages of Home Infusion Therapies to Fuel Their Adoption

The U.S. home infusion therapy market size touched USD 18.39 billion in 2023 and is predicted to reach USD 19.65 billion in 2024. The market is anticipated to touch USD 38.02 billion by 2032, recording a CAGR of 8.6% over 2024-2032.

Fortune Business Insights™ presents this information in its latest report titled “U.S. Home Infusion Therapy Market Size, Share & Industry Analysis, By Product (Devices, Drugs, and Services), By Indication (Enteral Nutrition, Anti-Infective, Chemotherapy, Hydration Therapy, Total Parenteral Nutrition, Immunoglobulins, and Others), and Forecast, 2024-2032”.

Home infusion therapy involves the subcutaneous or intravenous administration of medicines to patients undergoing treatment at home. This type of therapy has proven to be quite effective and safe for patients. The trend of giving healthcare treatments at home has gained significant momentum in recent years, which is expected to catalyze the adoption of home infusion therapies during the forecast period.

The COVID-19 pandemic had a positive impact on the U.S. home infusion therapy market growth as there was a robust demand for medical devices, such as infusion pumps. These pumps were extensively used to treat COVID-19-positive patients. Moreover, reputed regulatory authorities, such as the FDA authorized the use of infusion pumps in mAb therapies during emergencies. These factors boosted the market’s progress during this period.

Amedisys Entered Merger Deal With Optum Inc. to Offer Comprehensive Healthcare Solutions

Amedisys, a company offering infusion services, announced that it had finalized a merger deal with Optum Inc. The agreement, which was valued at USD 3.60 billion, was completed in the latter half of 2023. This move is expected to help both the organizations provide their patients with a comprehensive range of healthcare solutions, such as home infusion therapy. Optum is a provider of healthcare services powered by information and technology. The company offers cutting-edge and integrated medical solutions that accelerate the modernization of the healthcare system.

Economic & Clinical Advantages of Home Infusion Therapies to Fuel Their Adoption

The U.S. government and various healthcare agencies across the U.S. are promoting infusion therapy services among patients by highlighting their economic and clinical advantages. This factor has prompted several patients to opt for at-home healthcare treatments as they are quite cost-effective and reduce their risk of contracting infections. Offering home healthcare comes with several cost benefits, such as costs associated with examination fees, hospital visits, and inpatient stays. Moreover, patients can avoid the danger of contracting Hospital Acquired Infections (HAIs) by staying at home and receiving treatment. These factors are expected to boost the popularity of home infusion therapies among patients. In addition, the market has seen rise in the number of companies offering portable devices for the patients along with flexible payment and rental options.

However, several risks associated with the safety of administering various therapies at home can hamper the growth of this market. Moreover, the U.S. government does not have proper reimbursement policies for home infusion therapy in place, which can deter patients from opting for these treatments, further hindering the market’s growth.

Option Care Health Inc. Leads Market Growth Due to High Focus On Mergers & Acquisitions to Improve Product Portfolio

Some of the key companies operating in this market include Optum Inc., CVS Health, and Option Care Health Inc. These firms held a large U.S. home infusion therapy market share. Out of these organizations, Option Care Health is leading the market’s growth as the company is focusing on entering merger & acquisition deals and launching novel home infusion therapies and devices in the market. These moves will help Option Care Health enhance its existing product range and grow its customer base.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/u-s-home-infusion-therapy-market-106327

Notable Industry Development:

• September 2022 - CarepathRx revealed that it had signed a multi-year infusion management service agreement with Orlando Health to provide innovative and high-quality home infusion services. The new service claims to be affordable and convenient for patients.

List of the Companies Profiled in the Report:

• Option Care Health Inc. (U.S.)


• Optum Inc. (U.S.)


• CareCentrix Inc. (U.S.)


• CVS Health (U.S.)


• KabaFusion (U.S.)


• Promptcare Respiratory (U.S.)


• Baxter (U.S.)


• InfuSystem Holdings, Inc. (U.S.)


• Moog Inc. (U.S.)

Further Report Findings

• Based on product, the drugs segment held a dominant position in the U.S. home infusion therapy market in 2023 and is predicted to showcase a notable CAGR during the forecast period. One of the major factors contributing to the segment’s dominance is the growing prevalence of chronic diseases, such as cancer, multiple sclerosis, and autoimmune diseases. Moreover, many regulatory authorities across the U.S. are approving various infusion products, which is further fueling the segment’s growth.


• Based on indication, the enteral nutrition segment held the largest share of the market in 2023 due to the increasing number of people suffering from gastrointestinal ailments and diabetes needing enteral feeding.

Table of Segmentation